NHLBI last updated on: August 25, 2015
Font Size: increase font decrease font Reset
Home Centers News & Events Publications Newsletter Resources Links Contact Us Login
Homepage > Centers > Harvard - Broad Proteomics Center
NHLBI Proteomics Administrative and Coordination Center

Harvard - Broad Proteomics Center

Robert Gerszten

Director: Robert Gerszten, MD

Visit the website > 

The overall goal of our Center is to establish the infrastructure necessary for the discovery and validation of novel pathways and biomarkers triggered by myocardial ischemia. The multidisciplinary group of investigators in our Center contributes expertise in basic science, diagnosis and treatment of acute coronary syndromes, epidemiology and bioinformatics, basic and clinical chemistry, and proteomics. The Center is comprised of a consortium of cooperating institutions, including the Massachusetts General Hospital (MGH), Brigham and WomenÂ’s Hospital (BWH), the Thrombolysis In Myocardial Infarction (TIMI) Study Group, Harvard Medical School, the Beth Israel Deaconess Medical Center (BIDMC), and the Broad Institute.

Our work builds on our initial observations and working hypotheses that (1) an unbiased proteomics discovery platform will yield novel biomarkers and insights into pathways activated upon myocardial injury; (2) synergy exists between discovery efforts for clinical biomarkers and mechanistic models that will help identify the most robust pathways for further evaluation in both; (3) simultaneous assessment of multiple biomarkers examining different pathophysiological axes will provide complementary information to improve diagnosis and clarify prognosis, guide therapy, and provide targets for therapeutic modulation. Our discovery efforts will capitalize on unique animal models and clinical cohorts of patients undergoing planned myocardial injury, while our clinical validation efforts will benefit from the carefully phenotyped trial cohorts available at the TIMI Study Group. Our proposal will extend ongoing work in which we have established liquid chromatography-tandem mass spectrometry (LC-MS/MS) based discovery protocols to identify differentially expressed low abundance constituents of plasma and tissue, as well as targeted LC-MS-based assays to move quickly from discovery to initial target validation.






Not logged in   |   Log In
National Heart Lung and Blood Institute National Heart, Lung, and Blood Institute National Institutes of Health National Institutes of Health Department of Health and Human Services Department of Health and Human Services